In patients with acute myocardial infarction (AMI), the rate of microvascular embolization and no-reflow promoted by coronary stenting with the use of conventional techniques (CS) appears to be greater than the one that occurs with balloon angioplasty. The minor invasiveness of direct stenting (DS) of the infarct artery without predilation could be expected to reduce embolization in the coronary microvasculature and no-reflow in patients with AMI.
after stent deployment and expansion, suggesting that the negative effect on distal flow may be the consequence of increased atherosclerotic and thrombotic material embolization in the microvasculature.
Direct stenting (DS) without predilation is a new stenting technique that may reduce procedural time, radiation exposure time, and costs. [6] [7] [8] [9] [10] [11] [12] [13] [14] In addition to these advantages, DS could be expected to reduce embolization of plaque constituents and the incidence of the no-reflow phenomenon, thereby increasing perfusion and myocardial salvage in patients with AMI.
The aim of this prospective observational study was the assessment of the impact of DS of the infarct artery on the angiographic no-reflow phenomenon in patients with AMI.
Methods

Study cohort
The study included patients with AMI undergoing revascularization by infarct artery stent placement between December 1998 and May 2000. Criteria for enrollment included (1) chest pain persisting >30 minutes associated with ST-segment elevation of at least 0.1 mV in 2 or more contiguous electrocardiographic leads and (2) admission within 6 hours of symptom onset, as well as admission between 6 and 24 hours if there was evidence of continuing ischemia. Patients with cardiogenic shock resulting from predominant ventricular failure Primary infarct-related artery (IRA) stenting may be superior to conventional primary coronary angioplasty in patients with acute myocardial infarction (AMI). [1] [2] [3] [4] [5] Provisional infarct artery stent implantation improves the primary success rate, whereas elective stent implantation reduces the incidence of early and late infarct artery restenosis or reocclusion and related cardiac events, mainly the need for repeat target vessel revascularization. However, concluded randomized trials comparing primary infarct artery stenting and primary coronary angioplasty have shown no benefit of stenting in terms of reduction of the incidence of angiographic no-reflow phenomenon, which is strongly related to mortality. In the largest trial, infarct artery stenting was associated with a trend toward a lower incidence of Thrombolysis in Myocardial Infarction (TIMI) grade 3 flow at the end of the procedure compared with angioplasty alone. 5 On the other hand, an acute reduction of a normal angiographic flow after balloon angioplasty may be observed were included. No upper age limit was used. The exclusion criteria included (1) previous administration of fibrinolytic treatment and (2) inability to obtain informed consent.
Study protocol
Angiographic criteria for exclusion from mechanical intervention included (1) stenosis of the infarct artery <70% associated with TIMI grade 3 flow and (2) inability to identify the infarct artery. Infarct artery stenting was to be attempted in all patients with a reference vessel diameter ≥2.5 mm. Evidence of coronary thrombus, presence of diffuse disease, a major branch involved in the culprit lesion, left main disease, or severe vessel tortuosity were not considered contraindications to stenting. The decision whether to perform DS was made by the operator, and if the culprit vessel was considered suitable, an attempt was made to cross the lesion with a premounted stent. A persistent TIMI grade 0-1 flow after the wire crossed the occlusion was not a contraindication to DS. In these cases the morphologic features of the target vessel beyond the occlusion and the length of the target lesion were assessed by ultraselective intracoronary dye injection with use of a duallumen catheter (Multifunctional Probing, Schneider-Boston Scientific, Maple Grove, Minn). The stent was deployed and expanded with a single progessive balloon inflation. Postdilation with another balloon with very high pressures was allowed only in case of a suboptimal angiographic result after direct stent deployment and expansion. In patients with a target lesion not suitable for DS, a predilation was performed and then coronary stenting was accomplished by standard techniques. In all cases, the use of very high pressure (>16 atm) was discouraged. Abciximab was used at discretion of the operator. Abciximab was administered immediately before the procedure (0.25 mg/kg body weight followed by a 12-hour infusion at 10 mg/kg/min). In patients receiving abciximab heparin was continued for 12 hours, whereas in the remaining patients intravenous heparin was continued for 2 days after the procedure. Patients were routinely treated with aspirin (325 mg/d indefinitely) and ticlopidine (500 mg/d for 1 month). Coronary angiography was required for all patients at 48 to 72 hours and at 6 months after the procedure. Left ventriculography was performed in all patients if not contraindicated by cardiogenic shock or severe hemodynamic instability. Unscheduled angiography was allowed on the basis of clinical indication. A 12-lead electrocardiogram was recorded continuously 30 minutes after infarct artery recanalization. The ST-segment changes were evaluated in the single lead with the most prominent ST-segment elevation before mechanical intervention. ST-segment elevation was measured to the nearest 0.5 mm at 60 milliseconds after the J point with the aid of hand-held calipers. According to a previous report,15 reduction in ST-segment elevation was defined as a ≥50% decrease in ST-segment elevation 30 minutes after IRA recanalization. Creatine kinase (CK) measurements were systematically performed on admission and every 3 hours for the subsequent 24 hours and then every 12 hours for 2 days. The peak value of CK and the time-to-peak CK were estimated for each patient.
Angiographic analysis
Coronary flow in the infarct vessel was graded visually by the individual angioplasty operator according to the TIMI study group classification. 16 Collateral flow was graded by the classification developed by Rentrop et al. 17 No-reflow phenomenon was defined as a TIMI grade flow ≤2 not attributable to dissection, occlusive thrombosis, or epicardial spasm and that required intracoronary administration of adenosine, papaverine, or verapamil. Quantitative coronary angiography was performed as previously described with the use of an automatic edge detection system (Siemens Ancor, Solne, Sweden). 18 Coronary occlusion was assigned a value of 0 mm for minimal lumen diameter and 100% for percent diameter stenosis. Multivessel disease was defined as at least 1 major non-infarct-artery with >50% stenosis. Analysis was performed immediately after the procedure, at 48 to 72 hours, and at 6 months using identical projections. The left ventricular ejection fraction was calculated by digitization of the ventricular outline in diastolic and systolic frames from ventriculograms performed in the right anterior oblique projection.
End points
The primary end point of the study was the incidence of the angiographic no-reflow phenomenon. The secondary end points were (1) the reduction in ST-segment elevation at 30 minutes after intervention and (2) the time to peak CK.
Statistical analysis
Discrete data are summarized as frequencies, whereas continuous data are mean values ± SD. The χ 2 test or the Fisher exact test was used for comparison of categorical variables. A 2-tailed Student t test was used to test differences among continuous variables. Forward stepwise multivariate logistic regression analysis was used to identify correlates of the primary end point of no-reflow phenomenon. The factors analyzed included age (years), sex, diabetes, anterior AMI, previous myocardial infarction, cardiogenic shock, multivessel disease, preprocedure TIMI grade flow >1, Rentrop collateral flow grade >1, target lesion length (millimeters), time from symptom onset to recanalization (minutes), DS, final balloon inflation pressure (atmospheres), and abciximab administration. A P value <.05 was considered significant. Odds ratio and 95% confidence intervals were calculated. Analyses were performed with the software Statistica 4.5 (Statsoft, Tulsa, Okla) and SPSS 7.0 (SPSS, Chicago, Ill).
Results
Between December 1998 and May 2000, 468 patients with AMI underwent mechanical intervention. There were 7 primary angioplasty failures. Of the 461 patients with successful mechanical infarct artery recanalization, 38 (8%) did not have stent placement because of a reference vessel diameter <2.5 mm and 423 had infarct artery stenting (92%). DS was performed in 110 patients (26%), whereas conventional techniques (CS) with predilation were done in 313 (74%). Baseline clinical and angiographic characteristics of the 2 stent groups are summarized in Table I . The risk profile of the DS group were better compared with that of the CS group. The mean age in the DS group was lower, as was the incidence of diabetes, cardiogenic shock, multivessel disease, and multiple lesions within the infarct artery. A baseline TIMI grade flow >1 was more frequent in the DS group, and the reference vessel diameter was larger than the one in the CS group. Baseline left ventriculography was performed in 328 patients (92 of the DS group and 236 of the CS group). The mean left ventricular ejection fraction was similar in the 2 groups. Procedural characteristics are summarized in Table II . There were no stenting attempt failures in either group or stent loss or failed angiographic expansion of the stent during deployment. The stents implanted included the ACS Multilink Duet delivery system (Guidant, Temecula, Calif) in most patients of both groups, as well as the NIR stent mounted on Viva Primo or Activa balloon (Boston Scientific, Maple Grove, Minn), and the AVE GFX-II and AVE 670 (MedtronicApplied Vascular Engineering, Santa Rosa, Calif). Multiple stent implantation was performed more frequently in the CS group. The procedure time was shorter in the DS group.
A no-flow phenomenon occurred more frequently in the CS group than in the DS group (12% and 5%, respectively, P = .040).
The ST-segment reduction at 30 minutes was more frequent in the DS group (68%) than in the CS group (61%), but this difference did not reach significance (P = .163). In patients with no-reflow, the ST-segment reduction rate was lower compared with that of patients with TIMI grade 3 flow (27% and 67%, respectively, P < .001). Patients in both groups had similar peak values of CK (2388 ± 2080 U/L in the CS group and 2500 ± 2076 U/L in the DS group, P = .629) and time to peak CK from chest pain onset (11.5 ± 4.6 hours in the CS group and 11.2 ± 4.8 hours in the DS group, P = .637).
The 1-month clinical outcome is summarized in Table  III . The mortality rate was higher in the CS group than in the DS group (8% and 1%, respectively, P = .008). There were no differences between the CS group and the DS group in reinfarction rate and repeat target vessel revascularization rate. The need for repeat target vessel revascularization in all cases was due to occlusive dissection that was not evident in the angiogram immediately after the stenting procedure.
Patients with no-reflow had a mortality rate of 11%, whereas patients with TIMI grade 3 flow after stent implantation had a mortality rate of 5.6% (P = .142). Figure 1 shows the mortality rates in patients with noreflow and a normal flow after stent implantation and the rates of ST-segment reduction. The incidence of STsegment reduction was higher in patients with a TIMI grade 3 flow after stent implantation.
The results of the multivariate analyses are shown in Table IV . By multivariate analysis only age, a baseline patent infarct artery, and lesion length were related to the primary end point. A subsequent analysis in patients with a lesion length ≤15 mm showed that the 
Discussion
Potential advantages of DS in AMI
The rate of arterial embolization in the microvasculature after percutaneous coronary interventions is unexpectedly high. 19 In patients with angina the rate of arterial embolization complicated by myocardial infarction induced by stenting by a conventional technique appears to be greater than that occurring with balloon angioplasty. 20 It is likely that the pathologic substrate of AMI, including an already disrupted atherosclerotic plaque with superimposed thrombosis, may potentiate the bulk atherosclerotic platelet embolization promoted by catheter-based reperfusion therapy. It has been hypothesized that with CS techniques the single or multiple high-pressure balloon inflations after stent deployment, associated with a bulky effect of the expanding stent, may promote the embolization of atherosclerotic debris and thrombotic material extruded through the struts during the initial stent expansion. 5 Moreover, in animal models it has been shown that stent deployment and expansion with a single balloon inflation is associated with less vessel wall injury 21 and, as a consequence, it may be inferred, less disruption to distal flow produced by embolic material. Finally, coronary angioscopy performed after direct stent implantation in patients with AMI has shown that the stent exerts a "jailing" effect on thrombotic material (Guagliumi G, personal communication, Endovascular Therapies Course, Paris,
Figure 1
Mortality rates (A) and the rates of ST-segment reduction (B) in patients with no-reflow (black bars) and a normal flow after stent implantation (white bars).
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Table III. One-month clinical outcome
May 2000). Potential disadvantages of the DS technique are embolization promoted during target lesion crossing attempt, stent loss, and incomplete balloon and stent expansion in a "hard" calcified lesion. Enhanced designs of second-generation stents and delivery systems, as well as the enhanced crimping techniques, seem to overcome these potential limitations, whereas the risk of an undilatable lesion in the setting of AMI may be considered remote. In our series of patients DS was 100% successful and no stents were lost.
The no-reflow phenomenon
After successful infarct artery recanalization, myocardial perfusion may deteriorate as a result of microvascular dysfunction mediated by spasm, oxygen-free radical injury, neutrophil activation and plugging, local edema, and macroembolization and microembolization of the disrupted plaque and thrombus. There is evidence that embolization in the microvasculature after catheter-based interventions is extremely common and that it plays a central role in the impairment of myocardial perfusion even in the case of a brisk epicardial flow restored by mechanical intervention in patients with AMI. 22 The use of abciximab in avoiding platelet aggregation in the microvasculature may improve myocardial reperfusion, 23 whereas the efficacy of emboli entrapment devices is currently under investigation.
New angiographic methods, such as the corrected TIMI frame count 24 and myocardial blush grade 25 as well as myocardial contrast echography, 22 Doppler flow velocity measurement, and scintigraphic methods all allow the assessment of myocardial flow and microvascular function. However, several factors may prevent a correct evaluation of myocardial reperfusion after catheter-based interventions in the acute phase of myocardial infarction. First, microvascular dysfunction may improve in most patients only gradually within 2 weeks after intervention, 23 rendering the "snapshot" of flow in the acute phase of uncertain prognostic value. Second, frequently in the acute phase of myocardial infarction, flow is impaired not only in the area at risk but also in uninvolved artery territories, indicating that AMI may result in global flow delays. 26 Finally, all techniques have major logistic and technical limitations that prevent a correct assessment of reperfusion and potential microvascular function recovery.
In this study, we defined the no-reflow phenomenon as a TIMI grade <3 flow not attributable to epicardial spasm or obstruction after intervention. This conventional angiographic criterion clearly identifies a subset of patients with no-reflow resulting from severe microvascular dysfunction but does not identify those patients with no-reflow and impaired microvascular function but having a normal angiographic flow. However, several studies have shown that a TIMI grade 3 flow is a prerequisite of myocardial perfusion and salvage and improved survival and that a TIMI grade flow <3 after reperfusion therapy is associated with an adverse outcome. 5, [27] [28] [29] [30] [31] Moreover, to reduce the potential interobserver variability in the assessment of TIMI flow grade, only patients who needed intracoronary administration of adenosine, papaverine, or verapamil were considered as having no-reflow.
DS was associated with a decreased incidence of the no-reflow phenomenon compared with CS, suggesting that a less-invasive stenting technique may prevent severe flow disruption caused by embolization in the microvasculature. The variables that resulted independently related to the risk of no-reflow in the multivariate analysis were age, a preprocedural patent infarct artery, and lesion length. In this analysis, DS was not related to the risk of no-reflow. The absence of correlation between DS and no-reflow may be explained by the small sample size of the study or, more likely, by the predominant impact of plaque burden and extensive atherosclerotic disease on no-reflow. In fact, when the multivariate logistic regression analysis was performed in the subset of patients with a target lesion length ≤15 mm, the variables independently related to no-reflow were age, DS, and final balloon inflation pressure. On the other hand, the current selection process for DS is such that an evident bias is introduced because patients with extensive coronary disease or long lesions are not considered for DS (see below).
According to the results of previous studies, [27] [28] [29] [30] [31] noreflow had a negative prognostic significance being associated with a 2-fold increased 1-month mortality rate compared with patients with a TIMI grade 3 flow immediately after the revascularization procedure.
The selection of patients for DS of the IRA In this study patients who were not considered eligible for DS had more adverse baseline clinical and angiographic characteristics and the potential for a higher mortality rate compared with patients who underwent DS. Although DS was feasible and safe in a substantial minority of patients with AMI, the selection bias should be taken into account to assess the potential advantages of DS correctly. The unfavorable anatomic characteristics of DS, such as diffuse disease or multiple focal lesions within the infarct artery, and heavy calcification may explain the higher incidence of the no-reflow phenomenon in the CS group because the diffusion of atherosclerotic disease is a risk factor for embolization in the microvasculature. 32, 33 Nevertheless, there is no doubt that the increased invasiveness of the CS technique, with repeat balloon dilations, with respect to vessel wall injury may also be considered a dominant risk factor for embolization. When patients with a lesion length >15 mm were excluded from the analysis, DS and final balloon inflation pressure were both inde-pendently related to the risk of no-reflow. Paradoxically, the advantage of DS in the reduction of embolization could be superior in those anatomic settings currently considered unfavorable, such as long lesions or multiple lesions within the infarct artery. Thus further clinical randomized studies comparing DS with CS of the infarct artery should also include patients with unfavorable anatomic characteristics and at high risk because it could be very difficult or even impossible to show a benefit of DS in low-risk patients.
Study limitations
This is a prospective nonrandomized study. Therefore we call for caution in interpreting the results because of its relatively small sample size and because of the selection process used in assigning patients to DS or CS of the infarct artery. Nevertheless, this is the largest series of consecutive patients with AMI who underwent DS of the IRA, and patients were included in the study without any restriction on the basis of age or clinical status on presentation, thereby reflecting the real world of patients with AMI in current practice. In this series of patients abciximab administration did not appear to be related to the risk of no-reflow. This fact is likely to be a result of the small sample size. To evaluate prophylactic administration of abciximab in conjunction with DS, further studies are necessary. Despite these limitations, the results of this study suggest that DS in patients with AMI is feasible and safe and may reduce the incidence of the angiographic no-reflow phenomenon and decrease the occurrence of distal thromboembolism, thereby increasing ultimate effective myocardial reperfusion.
